Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Bristol-Myers Squibb. OPDUALAG™ (nivolumab and relatlimab-rmbw) injection, for intravenous use: US prescribing information. 2022. https://www.accessdata.fda.gov/. Accessed 26 Apr 2022.
2. Shi AP, Tang XY, Xiong YL, et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front Immunol. 2022;12(785091):1–11.
3. LaFleur MW, Muroyama Y, Drake CG, et al. Inhibitors of the PD-1 pathway in tumor therapy. J Immunol. 2018;200(2):375–83.
4. Barbari C, Fontaine T, Parajuli P, et al. Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci. 2020;21(14):5009.
5. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.
Cited by
95 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献